05 / Tirzepatide
Available as EIRA
| Sequence | 39-amino-acid synthetic peptide, backbone based on the GIP sequence, with a C20 fatty di-acid moiety conjugated via a linker at Lys20 |
|---|---|
| Formula | C225H348N48O68 |
| Class | Dual GIP and GLP-1 receptor agonist |
A single peptide that activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, studied in type 2 diabetes and obesity trials and approved as a pharmaceutical (Mounjaro, Zepbound). Peptheos supplies tirzepatide as a research reagent only. It is not the branded pharmaceutical and is not offered as a substitute for it.
Tirzepatide (development code LY3298176) was characterised in a 2018 study reporting activation of both GIP and GLP-1 receptor signalling in vitro and reductions in blood glucose, body weight, and food intake in diet-induced obese mice, alongside a phase 1 readout in adults with type 2 diabetes.
In SURPASS-2, an open-label 40-week phase 3 trial in 1,879 adults with type 2 diabetes on metformin, the trial examined tirzepatide at 5, 10, and 15 mg against semaglutide 1 mg, reporting greater mean reductions in glycated haemoglobin and body weight across all three doses.
In SURMOUNT-1, a 72-week phase 3 double-blind trial in 2,539 adults with obesity or overweight without diabetes, the trial examined 5, 10, and 15 mg once weekly against placebo, reporting mean weight reductions of 15.0%, 19.5%, and 20.9% at the three doses.
Library
Tirzepatide is a single 39-residue peptide that activates two incretin receptors, GIP and GLP-1. Its phase 3 trials in type 2 diabetes and obesity are among the largest in the field. It is also an approved pharmaceutical, which sets it apart from most compounds in this library.
For research purposes only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.
